Abstract
Endogenous interleukin (IL)-12 plays a pivotal role in promoting cell-mediated immunity against intracellular pathogens. Uncontrolled cell-mediated immune responses, however, may lead to chronic inflammation and autoimmune disease. Unfortunately, treatment of either infection or autoimmunity with immunomodulating drugs always incur the danger of favouring the other form of disease. The recent discovery of the dimeric IL-12-related cytokine IL-23 adds to our understanding of the fine tuning of cellular immunity. Only recently, studies revealed IL-23, and not IL-12, to be the decisive factor in this immune deviation and a variety of autoimmune disorders have now been shown to be strikingly dependent on IL-23. Therefore, targeting of IL-23-mediated, rather than IL-12-dependent, mechanisms represent a promising therapeutic approach for autoimmune diseases. The invention of aptamers that are capable of neutralising IL-23 and/or IL-12 and their potential use as autoimmune disease therapeutics will be discussed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
